Cytosorbents Corp ( (CTSO) ) has released its Q3 earnings. Here is a breakdown of the information Cytosorbents Corp presented to its investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CytoSorbents Corporation is a company specializing in blood purification technologies, primarily used in intensive care units and cardiac surgery to treat life-threatening conditions. In its third-quarter 2025 financial report, CytoSorbents announced a 10% year-over-year revenue increase, reaching $9.5 million, driven by strong performance in distributor territories and direct sales outside Germany. The company also reported an improved gross margin of 70% and a reduced operating loss of $2.9 million compared to the previous year.
Key highlights from the report include an amended credit agreement with Avenue Capital Group, providing an additional $2.5 million in funding and extending the interest-only period, as well as the implementation of a Workforce and Cost Reduction Program aimed at achieving cash-flow breakeven by Q1 2026. Additionally, CytoSorbents submitted a pre-submission package for DrugSorb-ATR to the FDA, with a regulatory decision anticipated by mid-2026.
The company’s strategic initiatives and financial performance reflect a positive trajectory, with expectations of improved performance in the German market and continued growth in other regions. The recent clinical data publications further support the effectiveness of CytoSorbents’ technologies in managing critical conditions.
Looking ahead, CytoSorbents remains focused on advancing its strategic initiatives, including the potential approval and launch of DrugSorb-ATR in the US, and achieving cash-flow breakeven in early 2026. The company is optimistic about its ability to sustain growth and innovation in the blood purification sector.